Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407179 | 0.87 | CRHR1 (0.40) | CRHR1TLR8 | |
| SCHEMBL1408048 | 0.85 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL1407200 | 0.85 | NR1H2 (0.45) | P2RX7 | |
| SCHEMBL4026238 | 0.84 | ESR1 (0.43) | — | |
| SCHEMBL1407448 | 0.84 | NR1H2 (0.47) | P2RX7 | |
| SCHEMBL4035086 | 0.83 | CRHR1 (0.39) | CRHR1TLR8GPR139P2RX7 | |
| SCHEMBL4200871 | 0.82 | NR1H2 (0.43) | CRHR1GPR139 | |
| SCHEMBL1407707 | 0.82 | NR1H2 (0.43) | P2RX7 | |
| SCHEMBL1408171 | 0.82 | KMT2A (0.48) | — | |
| SCHEMBL1408459 | 0.81 | NR1H2 (0.48) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | CRHR1 2217/4885TLR8 288/4885GPR139 497/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | CRHR1 2181/4885TLR8 108/4885GPR139 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.